PL376231A1 - Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate - Google Patents

Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate

Info

Publication number
PL376231A1
PL376231A1 PL03376231A PL37623103A PL376231A1 PL 376231 A1 PL376231 A1 PL 376231A1 PL 03376231 A PL03376231 A PL 03376231A PL 37623103 A PL37623103 A PL 37623103A PL 376231 A1 PL376231 A1 PL 376231A1
Authority
PL
Poland
Prior art keywords
inhalation
salmeterol xinafoate
powdered medicament
tiotropium salt
tiotropium
Prior art date
Application number
PL03376231A
Other languages
Polish (pl)
Inventor
Hagen Graebner
Mareke Hartig
Peter Sieger
Rainer Soyka
Michael Trunk
Michael Walz
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32404034&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL376231(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg
Publication of PL376231A1 publication Critical patent/PL376231A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL03376231A 2002-12-20 2003-12-04 Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate PL376231A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10259912 2002-12-20

Publications (1)

Publication Number Publication Date
PL376231A1 true PL376231A1 (en) 2005-12-27

Family

ID=32404034

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03376231A PL376231A1 (en) 2002-12-20 2003-12-04 Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate

Country Status (21)

Country Link
EP (1) EP1581198A1 (en)
JP (1) JP2006516135A (en)
KR (1) KR20050086930A (en)
CN (1) CN1728988B (en)
AU (1) AU2003288226B2 (en)
BR (1) BR0317443A (en)
CA (1) CA2510779A1 (en)
DE (1) DE10351663A1 (en)
EA (1) EA010588B1 (en)
EC (1) ECSP055855A (en)
FR (1) FR2848849B1 (en)
HR (1) HRP20050570A2 (en)
IT (1) ITMI20032473A1 (en)
MX (1) MXPA05006519A (en)
NO (1) NO20053548L (en)
NZ (1) NZ541303A (en)
PL (1) PL376231A1 (en)
RS (1) RS20050484A (en)
UA (1) UA83813C2 (en)
WO (1) WO2004058233A1 (en)
ZA (1) ZA200503692B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
JP4342426B2 (en) * 2004-11-24 2009-10-14 科研製薬株式会社 Itraconazole formulation for oral administration
JP2009504603A (en) * 2005-08-06 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Method of treating dyspnea by administering a combination of tiotropium salt and salmeterol salt
PT1869035E (en) * 2005-12-19 2013-01-10 Sicor Inc Novel crystalline form of tiotropium bromide and process for preparation thereof
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
BRPI0711558A2 (en) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polymorphs
DE102007036411A1 (en) * 2007-07-20 2009-02-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg powder inhaler
PE20090907A1 (en) * 2007-07-21 2009-08-05 Boehringer Ingelheim Int NEW POWDER DRUGS CONTAINING THOTROPE AND SALMETEROL, AS WELL AS LACTOSE AS AN EXCIPIENT
PE20140960A1 (en) 2008-04-03 2014-08-15 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
BRPI0916997A2 (en) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh DPP-4 INHIBITOR AND ITS USE
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
EA034869B1 (en) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Treatment of genotyped diabetic patients with dpp-4 inhibitors such as linagliptin
MX341025B (en) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Combination therapy.
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (en) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Xanthine derivatives as DPP-4 inhibitors for the treatment of glomerular epithelial cell related disorders and / or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
KR101748796B1 (en) * 2015-09-30 2017-06-19 한미약품 주식회사 Inhalation capsule with enhanced delivery rate of active ingredients
CN109310697A (en) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 Combination of linagliptin and metformin
AU2019380421B2 (en) 2018-11-13 2025-07-24 Cocrystal Pharma, Inc. Formulations of influenza therapeutics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1056974C (en) * 1992-02-11 2000-10-04 格拉克索公司 Drug material suitable for micronisation
WO1993016031A1 (en) * 1992-02-11 1993-08-19 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DE19921693A1 (en) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
DE10056104A1 (en) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Drug compositions useful for treatment of respiratory diseases, especially asthma and chronic obstructive pulmonary disease comprises tiotropium salts and salmeterol salts
DE10104367A1 (en) * 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Medicinal compositions containing betamimetics with fewer side effects
DE10130371A1 (en) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics, corticosteroids and betamimetics
JP2004537377A (en) * 2001-08-09 2004-12-16 グラクソ　グループ　リミテッド Inhalation device with pharmaceutical composition
EP1429768B1 (en) * 2001-09-14 2016-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Novel medicaments for inhalation

Also Published As

Publication number Publication date
FR2848849B1 (en) 2007-01-05
NO20053548L (en) 2005-09-02
AU2003288226A1 (en) 2004-07-22
MXPA05006519A (en) 2005-08-26
UA83813C2 (en) 2008-08-26
EA200500902A1 (en) 2006-02-24
NZ541303A (en) 2008-11-28
CN1728988A (en) 2006-02-01
HRP20050570A2 (en) 2006-07-31
CA2510779A1 (en) 2004-07-15
KR20050086930A (en) 2005-08-30
AU2003288226B2 (en) 2010-01-07
EA010588B1 (en) 2008-10-30
BR0317443A (en) 2005-11-16
ITMI20032473A1 (en) 2004-06-21
RS20050484A (en) 2007-11-15
DE10351663A1 (en) 2004-07-01
FR2848849A1 (en) 2004-06-25
WO2004058233A1 (en) 2004-07-15
EP1581198A1 (en) 2005-10-05
CN1728988B (en) 2010-04-28
JP2006516135A (en) 2006-06-22
ECSP055855A (en) 2005-11-22
ZA200503692B (en) 2006-10-25

Similar Documents

Publication Publication Date Title
IL183623A0 (en) A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation
IL156308A0 (en) Metered dose inhaler for salmeterol xinafoate
EP1581281A4 (en) Inhalation device for producing a drug aerosol
IL182634A0 (en) Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy
EG23792A (en) Inhalation device for transpulmonary administration
GB0313604D0 (en) Delivery device for powdered medicament
IL221103B (en) Inhaler for powdered substances particularly medical substances
PL387118A1 (en) Inhalation capsules comprising tiotropium and the use thereof
SI1335728T1 (en) Medicament compositions based on tiotropium salts and on salmeterol salts
EP1898922A4 (en) Improved drug or pharmaceutical compounds and a preparation thereof
GB0222295D0 (en) Breath actuated medicament dispensing devices
EP1685865A4 (en) SYRINGE FOR PREMIXING DRUGS IN POWDER
IL183929A0 (en) Use of inerferon - ?? in the preparation of a medicament
UA83813C2 (en) Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate
GB0328630D0 (en) Metered dose inhalation preparations
GB0714907D0 (en) A resonating (alerting) metered dose inhaler
EP1654312A4 (en) Pharmaceutical metered dose inhaler and methods relating thereto
PL371204A1 (en) Aerosol formulation for inhalation comprising a tiotropium salt
PL376229A1 (en) Pulverulent formulation for inhalation containing tiotropium
GB2406096B (en) A pharmaceutical metered dose aerosol inhaler device
TWI340649B (en) A pharmaceutical composition containing alkaline medicament
ZA200406881B (en) Medicaments containing betamimetic drugs and a novel anticholineterase drug
GB0226274D0 (en) Metered dose inhalation preparations
AU6028101A (en) Medicament for combating respiratory depression
GB0311701D0 (en) Improved metered dose inhaler product

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)